Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Technologies : Early Career Professor Award Presented to Jason H. Yang

07/28/2021 | 08:04am EST

Rutgers, The State University of New Jersey, professor recognized for research into the biological mechanisms underlying chronic and infectious diseases

Agilent Technologies Inc. (NYSE: A) today announced that Jason H. Yang, Ph.D., has received the 2021 Agilent Early Career Professor Award. Dr. Yang is an assistant professor of Microbiology, Biochemistry and Molecular Genetics in the Center for Emerging and Re-Emerging Pathogens at Rutgers New Jersey Medical School. This year’s award focus was contributions to the development of breakthrough solutions to understand or manage immunological responses to infection, autoimmunity, or cancer.

Dr. Yang’s multidisciplinary research program integrates high-throughput, quantitative experimentation with network modeling and machine learning to study mechanisms underlying the progression and cure of human diseases. The Agilent Early Career Professor Award will support research that reverse engineers the cell circuitry of human macrophages to enable the development of synthetically engineered macrophages as new cell-based therapies for treating infections, autoimmunity, and cancer.

“It is an immense honor to be named for this year’s prestigious Agilent Early Career Professor Award. This competitive award will enable us to expand our research capabilities and allow us to make new quantitative, real-time measurements into understanding how immune cells make cellular decisions,” said Yang. “We are excited about the new discoveries this award will help unlock and about the new relationship we will build with Agilent as our work at Rutgers moves forward.”

“Dr. Yang’s innovative research leverages an integrated set of expertise in network modeling and machine learning tools, with high-throughput, quantitative experimentation to accelerate the discovery of biological mechanisms underlying the function of the human immune system,” said Jack Wenstrand, Ph.D., director of University Relations and External Research at Agilent. “We are delighted to contribute to and accelerate Dr. Yang’s research, and we are confident that his methods, his discoveries, and the students he will advise will be influential in the research community and will translate to improvements in human health.”

Dr. Yang was selected as the 2021 recipient because of his focus on developing innovative therapies for chronic and infectious diseases using systems biology and synthetic biology approaches. Dr. Yang joined Rutgers New Jersey Medical School in 2019 as an assistant professor. He has developed interpretable machine learning approaches for studying cellular phenotypes associated with human disease by applying biological network models as tools to enhance the interpretability of machine learning models. Dr. Yang’s lab is now extending these approaches to tackle the global health challenges posed by antimicrobial resistance, tuberculosis, and cardiovascular disease.

The Agilent Early Career Professor Award is an annual program that recognizes and supports promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the Agilent Early Career Professor Award is available at Agilent.com.

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.


© Business Wire 2021
All news about AGILENT TECHNOLOGIES, INC.
12/06Agilent Announces the Cary 3500 UV-Vis Spectrophotometer Compatibility with OpenLab
BU
11/23Agilent to Present at Evercore ISI Virtual Healthcare Conference
BU
11/23Stifel Adjusts Price Target for Agilent Technologies to $169 From $162, Maintains Hold ..
MT
11/23SVB Leerink Adjusts Agilent Technologies' Price Target to $175 from $170, Keeps Outperf..
MT
11/23Health Care Stocks Flat Ahead of Tuesday's Opening Bell
MT
11/22AGILENT TECHNOLOGIES : Prepared Remarks (opens in new window)
PU
11/22AGILENT : Fiscal Q4 Earnings Snapshot
AQ
11/22Agilent Technologies Fiscal Q4 non-GAAP EPS, Revenue Rise
MT
11/22AGILENT TECHNOLOGIES : Reports Fourth-Quarter and Fiscal Year 2021 Financial Results - For..
PU
11/22Earnings Flash (A) AGILENT TECHNOLOGIES Posts Q4 Revenue $1.66B, vs. Street Est of $1.6..
MT
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 318 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 43,4x
Yield 2021 0,50%
Capitalization 45 853 M 45 853 M -
EV / Sales 2021 7,49x
EV / Sales 2022 6,92x
Nbr of Employees 17 000
Free-Float 100,0%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 151,47 $
Average target price 173,80 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Boon Hwee Koh Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGILENT TECHNOLOGIES, INC.25.08%45 853
THERMO FISHER SCIENTIFIC33.59%245 196
DANAHER CORPORATION38.16%219 304
INTUITIVE SURGICAL, INC.17.94%115 663
SIEMENS HEALTHINEERS AG51.93%80 663
EDWARDS LIFESCIENCES CORPORATION20.38%69 900